Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Soft Tissue Infections | 2 | 2018 | 116 | 0.77 | Why? |
| Joints | 1 | 2018 | 97 | 0.67 | Why? |
| Streptococcus agalactiae | 1 | 2018 | 194 | 0.65 | Why? |
| Arthritis, Infectious | 1 | 2018 | 111 | 0.64 | Why? |
| Osteomyelitis | 1 | 2018 | 131 | 0.63 | Why? |
| Skin Diseases, Infectious | 1 | 2017 | 77 | 0.62 | Why? |
| Bone and Bones | 1 | 2018 | 235 | 0.60 | Why? |
| Streptococcal Infections | 1 | 2018 | 255 | 0.56 | Why? |
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 46 | 0.50 | Why? |
| Aromatase Inhibitors | 1 | 2013 | 45 | 0.50 | Why? |
| Singapore | 14 | 2021 | 3641 | 0.49 | Why? |
| Receptors, Estrogen | 1 | 2013 | 171 | 0.46 | Why? |
| Cell Cycle Proteins | 1 | 2013 | 297 | 0.42 | Why? |
| Neovascularization, Pathologic | 1 | 2013 | 305 | 0.38 | Why? |
| Anti-Bacterial Agents | 5 | 2020 | 10083 | 0.24 | Why? |
| Leukocidins | 2 | 2018 | 47 | 0.22 | Why? |
| Exotoxins | 2 | 2018 | 54 | 0.22 | Why? |
| Staphylococcal Skin Infections | 2 | 2017 | 32 | 0.22 | Why? |
| Liver Abscess | 1 | 2020 | 42 | 0.21 | Why? |
| Bacterial Toxins | 2 | 2018 | 185 | 0.19 | Why? |
| Ceftriaxone | 2 | 2020 | 365 | 0.19 | Why? |
| Cloxacillin | 1 | 2017 | 14 | 0.18 | Why? |
| Staphylococcal Infections | 2 | 2017 | 1099 | 0.17 | Why? |
| Infusions, Parenteral | 1 | 2017 | 41 | 0.17 | Why? |
| Fasciitis, Necrotizing | 1 | 2018 | 56 | 0.17 | Why? |
| Eye Protective Devices | 1 | 2020 | 245 | 0.17 | Why? |
| Leukoencephalopathies | 1 | 2020 | 230 | 0.17 | Why? |
| Skin Diseases, Bacterial | 1 | 2018 | 105 | 0.16 | Why? |
| Colistin | 1 | 2018 | 217 | 0.15 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.15 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.15 | Why? |
| Patients' Rooms | 1 | 2020 | 675 | 0.14 | Why? |
| Yellow Fever | 1 | 2018 | 231 | 0.14 | Why? |
| Environmental Microbiology | 1 | 2020 | 575 | 0.14 | Why? |
| Prosthesis-Related Infections | 1 | 2018 | 302 | 0.14 | Why? |
| Breast Neoplasms | 1 | 2013 | 3633 | 0.14 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.14 | Why? |
| Outpatients | 2 | 2017 | 3417 | 0.13 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 711 | 0.13 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.13 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.12 | Why? |
| Outpatient Clinics, Hospital | 1 | 2017 | 523 | 0.12 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.11 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Patient Isolation | 2 | 2020 | 3182 | 0.10 | Why? |
| Dengue Virus | 1 | 2017 | 910 | 0.10 | Why? |
| Medical Audit | 1 | 2010 | 218 | 0.09 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.09 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.07 | Why? |
| Influenza, Human | 1 | 2010 | 10779 | 0.07 | Why? |
| Polymerase Chain Reaction | 3 | 2020 | 6740 | 0.07 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.06 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.06 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.06 | Why? |
| Travel | 1 | 2020 | 7220 | 0.05 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.05 | Why? |
| Male | 12 | 2021 | 367725 | 0.05 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.05 | Why? |
| Humans | 21 | 2021 | 930598 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Pyomyositis | 1 | 2018 | 12 | 0.05 | Why? |
| Gas Gangrene | 1 | 2018 | 8 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Mupirocin | 1 | 2017 | 22 | 0.05 | Why? |
| Adult | 9 | 2021 | 244371 | 0.05 | Why? |
| Dermatomycoses | 1 | 2018 | 55 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.04 | Why? |
| Yellow Fever Vaccine | 1 | 2018 | 198 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2018 | 27595 | 0.04 | Why? |
| Chlorhexidine | 1 | 2017 | 176 | 0.04 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.04 | Why? |
| Communicable Diseases, Emerging | 1 | 2010 | 2523 | 0.04 | Why? |
| Particle Size | 1 | 2020 | 1052 | 0.04 | Why? |
| Klebsiella pneumoniae | 1 | 2020 | 658 | 0.03 | Why? |
| Pets | 1 | 2017 | 314 | 0.03 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Gram-Negative Bacteria | 1 | 2018 | 473 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Substance Abuse, Intravenous | 1 | 2018 | 411 | 0.03 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.03 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.02 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Particulate Matter | 1 | 2020 | 3249 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Dengue | 1 | 2017 | 1565 | 0.02 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.02 | Why? |
| Zoonoses | 1 | 2017 | 3034 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Chan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(134)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(116)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_